EMMA News and Press, Emmaus Life Sciences Incorporation From 11/12/21

Emmaus Life Sciences Reports Third Quarter Financial Results and Business Highlights -- Net Revenues Increased 4% for the Nine Months Ended September 30, 2021 -- PR Newswire TORRANCE, Calif. , Nov. 12, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQ...

Emmaus Life Sciences Announces Partnership with UpScript to Provide Telehealth Solutions to Sickle Cell Disease Patients Partnership Will Expand Patient Access to Endari® PR Newswire TORRANCE, Calif. , Nov. 11, 2021 /PRNewswire/ -- Emmaus Life Sciences...

Torrance, California--(Newsfile Corp. - November 8, 2021) - Emmaus Life Sciences, Inc. (OTCQX: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that Yutaka Niihara, M.D., M.P.H., Chairman and Chief Executive Officer of...

Emmaus Life Sciences (OTCPK:EMMA) has entered into an agreement with Asembia to provide expanded patient and provider support services in order to simplify access to Endari, the company's prescription L-glutamine oral powder for the treatment of sickle cell disease. Asembia will provide a sin...

Emmaus Life Sciences Enters into Agreement with Asembia to Provide Expanded Patient Support Services PR Newswire TORRANCE, Calif. , Nov. 4, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) , a commercial-stage biopharmaceutical compa...

Emmaus Life Sciences Submits Application for U.A.E. Marketing Authorization for Endari® PR Newswire TORRANCE, Calif. , Oct. 26, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA) a commercial-stage biopharmaceutical company and leader in...

Emmaus Life Sciences Acquires Key Intellectual Property Rights to Novel IRAK4 Inhibitor From Kainos Medicine Agreement Expands on the Companies' Collaboration for the Preclinical Development of Potential Anti-Cancer Therapies PR Newswire TORRANCE, Calif. ...

OTC Markets Group Welcomes Emmaus Life Sciences, Inc. to OTCQX PR Newswire NEW YORK , Sept. 8, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 11,000 U.S. and global securities, today announced Emmaus Life Scienc...

Emmaus Life Sciences Reports Financial Results for the Six Months Ended June 30, 2021 Company Now Current with SEC Reporting Obligations PR Newswire TORRANCE, Calif. , Sept. 2, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTC: EMMA) , a commercial-sta...

Emmaus Life Sciences Announces Bahrain Temporary License of Endari® License Permits Importation and Early Access to Patients Pending Marketing Authorization PR Newswire TORRANCE, Calif. , Aug. 17, 2021 /PRNewswire/ -- Emmaus Life Sciences, Inc....